MALVERN, Pa., May 5, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from the phase 1 randomized, placebo-controlled clinical study of SHAPE (formerly SHP-141) in Stage IA –IIA Cutaneous T Cell Lymphoma will be presented at the annual Society of Investigative Dermatology Meeting to be held in Albuquerque, New Mexico from May 7– May 10, 2014.
Help employers find you! Check out all the jobs and post your resume.
